lunes, 9 de octubre de 2017

Late Effects of Treatment for Childhood Cancer (PDQ®)—Health Professional Version - National Cancer Institute

Late Effects of Treatment for Childhood Cancer (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version



SECTIONS

Changes to This Summary (09/28/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
This section was comprehensively reviewed and extensively revised.
This section was comprehensively reviewed and extensively revised.
Revised text about a study of 670 survivors of Hodgkin lymphoma who have lived 10 or more years that found myocardial infarction and structural heart defects were the major contributors to the excess grade 3 to grade 5 cumulative burden in survivors.
Added text about dexrazoxane’s association with secondary cancers (cited Chow et al., Tebbi et al., and Walker et al. as references 41, 42, and 43, respectively).
Added text about the results of a study of 3,172 5-year survivors of childhood cancer who received 10 Gy or higher to the Circle of Willis and at age 45 years the cumulative incidence of stroke was 11.3% (cited El-Fayech et al. as reference 51).
This section was comprehensively reviewed and extensively revised.
Added text to state that the prefrail phenotype is characterized by having two of five characteristics (low muscle mass, self-reported exhaustion, low energy expenditure, slow walking speed, and weakness) and the frail phenotype is characterized by having three or more of these characteristics.
This section was comprehensively reviewed and extensively revised.
Added text about a Childhood Cancer Survivor Study that compared self-reported pulmonary outcomes and their impact on daily activities among 5-year cancer survivors and a sibling cohort noting that by age 45 years, the cumulative incidence of any pulmonary condition was 29.6% for survivors (cited Dietz et al. as reference 4).
This section was comprehensively reviewed and extensively revised.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: September 28, 2017

No hay comentarios:

Publicar un comentario